InvestorsHub Logo

TrueTrades

05/23/17 2:35 PM

#2277 RE: nonewname1 #2275

imo nemus has paths too well planned to need to pivot
any changes in policy will only be advantageous for nemus
everybody says something
nemus quietly executes
i am no expert on the different cannabinoids in play
nemus has less hype and gets ducks lined up better before major moves and those moves are very near
imo

Vinpat

05/23/17 3:17 PM

#2278 RE: nonewname1 #2275

Even if the FDA changed their stance which I doubt, synthetic is cheaper to manufacture and much easier to achieve required purity standards. Having huge grows to meet drug demand is costly and risky. It's essentially medical marijuana with somewhat higher standards than what's currently available. There isn't much separation and there's a low barrier to entry. I just looked at one of the trials Tetra is doing which is trying to show that their drug can be safely smoked. Are you kidding me? Find me one FDA approved drug where the method of administration is smoking. They have a $100 million market cap? On what? It looks to me like they don't know what they are. Are they a medical marijuana company looking to be able to generate income in the short term without FDA approvals or are they a true biotech? If they're the latter then they are way behind Nemus and if they're wasting money on a drug that can be smoked then I'd run.

Nemus could have used the plant. They could grow all they wanted but they know it's not the future. I'd loosely compare it to heroin vs. the synthetic pain medications. Which one has more purity, more efficient dosing, which one does insurance cover and which one will doctors prescribe?